


Amendments to the ClaimsListing of the Claims:

1. (Currently Amended) A compound of formula I



wherein


m is from 1 to 5;

R<sub>1</sub> is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by a heterocyclic radical or by heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R<sub>4</sub>-lower alkyl-X-, wherein R<sub>4</sub> is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R<sub>1</sub> substituents are selected independently of one another if m>1;

~~or two vicinal R<sub>1</sub> substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

R<sub>2</sub> is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical;

R<sub>3</sub> is hydrogen or a radical of the formula Ia



wherein n is from 0 to 5; and

Z is halogen; unsubstituted or substituted lower alkyl; or free, etherified or esterified hydroxy; wherein the Z substituents are selected independently of one another if  $n > 1$ ; ~~or two vicinal Z substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~ and

$R_3'$  is hydrogen if  $R_3$  is a radical of the formula Ia or  $R_3'$  is a radical of the formula Ia as defined for  $R_3$  if  $R_3$  is hydrogen;

with the proviso that  $R_1$  is not methoxy if m and n are both 1,  $R_2$  is hydrogen and Z is fluoro; or a salt of the said compounds.

2. (Currently Amended) A compound of formula I according to claim 1, wherein m is an integer from 1 to 5;

$R_1$  is unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by a heterocyclic radical; a radical  $R_4$ -lower alkyl-X-, wherein  $R_4$  is hydrogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical  $R_5$ -C(=O)-, wherein  $R_5$  is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the  $R_1$  substituents are selected independently of one another if  $m > 1$ ;

~~or two vicinal  $R_1$  substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

$R_2$  is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical;

$R_3$  is a radical of the formula Ia, wherein n is from 1 to 5 and Z is halogen; unsubstituted or substituted lower alkyl; or free, etherified or esterified hydroxy; wherein the Z substituents are selected independently of one another if  $n > 1$ ;

~~or two vicinal Z substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~ and

$R_3'$  is hydrogen;

with the proviso that  $R_1$  is not methoxy if m and n are both 1,  $R_2$  is hydrogen and Z is fluoro; or a salt thereof.

3. (Currently Amended) A compound of formula I according to claim 2, wherein m is an integer from 1 to 5;

$R_1$  is unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by a heterocyclic radical; a radical  $R_4$ -lower alkyl-X-, wherein  $R_4$  is hydrogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical  $R_5$ -C(=O)-, wherein  $R_5$  is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the  $R_1$  substituents are selected independently of one another if  $m > 1$ ;

~~or two vicinal  $R_1$  substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

$R_2$  is hydrogen;

$R_3$  is a radical of the formula Ia, wherein n is from 1 to 5 and Z is halogen; unsubstituted or substituted lower alkyl; or free, etherified or esterified hydroxy; wherein the Z substituents are selected independently of one another if  $n > 1$ ;

~~or two vicinal Z substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring; and~~

$R_3'$  is hydrogen;

with the proviso that  $R_1$  is not methoxy if m and n are both 1,  $R_2$  is hydrogen and Z is fluoro; or a salt thereof.

4. (Currently Amended) A compound of formula I according to claim 2, wherein m is an integer from 1 to 3;

$R_1$  is amino-sulfonyl; mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by a heterocyclic radical; a radical  $R_4$ -lower alkyl-X-, wherein  $R_4$  is hydrogen, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical  $R_5$ -C(=O)-, wherein  $R_5$  is lower alkyl, free or etherified hydroxy, or a heterocyclic radical; wherein the  $R_1$  substituents are selected independently of one another if  $m > 1$ ;

~~or two vicinal  $R_1$  substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

$R_2$  is hydrogen;

$R_3$  is a radical of the formula Ia, wherein n is from 1 to 3 and Z is halogen; lower alkyl; or free or etherified hydroxy; wherein the Z substituents are selected independently of one another if  $n > 1$ ;

~~or two vicinal Z substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring; and~~

R<sub>3</sub>' is hydrogen;

with the proviso that R<sub>1</sub> is not methoxy if m and n are both 1, R<sub>2</sub> is hydrogen and Z is fluoro; or a salt thereof.

5. (Currently Amended) A compound of formula I according to claim 1, wherein m is an integer from 1 to 3;

R<sub>1</sub> is lower alkyl-sulfonyl; amino-sulfonyl; N,N-di-lower alkylamino; piperazinyl; lower alkyl-piperazinyl; tetrazolyl; lower alkyl substituted by lower alkyl-piperazinyl, hydroxy-lower alkyl-piperazinyl, piperidyl-amino or piperidyl-oxy wherein the piperidyl moiety is substituted by 1 to 4 lower alkyl radicals; a radical R<sub>4</sub>-lower alkyl-X-, wherein R<sub>4</sub> is hydrogen, halogen, N,N-di-lower alkylamino, morpholinyl or lower alkyl-piperidyl, and X is -S- or -O-; or a radical R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is lower alkyl, hydroxy, lower alkoxy or lower alkyl-piperazinyl; wherein the R<sub>1</sub> substituents are selected independently of one another if m>1;

~~or two vicinal R<sub>1</sub> substituents together with the phenyl carbon atoms to which they are attached form a thiazol or 1-oxo-thiazol ring;~~

R<sub>2</sub> is hydrogen, lower alkyl, N,N-di-lower alkylamino-lower alkyl, lower alkyl-piperidyl or lower alkyl-piperidyl-lower alkyl;

R<sub>3</sub> is a radical of the formula Ia, wherein n is 0, 1 or 2 and Z is halogen, lower alkyl, tri-halogen-lower alkyl, hydroxy, lower alkoxy or phenyl-lower alkoxy; wherein the Z substituents are selected independently of one another if n is 2;

~~or two Z radicals together form a dioxol ring; and~~

R<sub>3</sub>' is hydrogen;

with the proviso that R<sub>1</sub> is not methoxy if m and n are both 1, R<sub>2</sub> is hydrogen and Z is fluoro; or a salt thereof.

6. (Currently Amended) A compound of formula I according to claim 2, wherein m is an integer from 1 to 3;

R<sub>1</sub> is amino-sulfonyl; N,N-di-lower alkylamino; lower alkyl-piperazinyl; lower alkyl substituted by lower alkyl-piperazinyl; a radical R<sub>4</sub>-lower alkyl-X-, wherein R<sub>4</sub> is hydrogen, N,N-di-lower alkylamino, morpholinyl or lower alkyl-piperidyl, and X is -S- or -O-; or a radical R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is lower alkyl, hydroxy, lower alkoxy or lower alkyl-piperazinyl; wherein the R<sub>1</sub> substituents are selected independently of one another if m>1;

~~or two vicinal R<sub>1</sub> substituents together with the phenyl carbon atoms to which they are attached form a thiazol or 1-oxo-thiazol ring;~~

R<sub>2</sub> is hydrogen;

$R_3$  is a radical of the formula Ia, wherein n is 1 or 2 and Z is halogen, lower alkyl, hydroxy, lower alkoxy or phenyl-lower alkoxy; wherein the Z substituents are selected independently of one another if n is 2;

~~or two Z radicals together form a dioxol ring; and~~

$R_3'$  is hydrogen;

with the proviso that  $R_1$  is not methoxy if m and n are both 1,  $R_2$  is hydrogen and Z is fluoro; or a salt thereof.

7. (Previously Presented) A compound of formula I according to claim 1, with the proviso that  $R_1$  is not a radical  $R_4$ -lower alkyl-X-, or a salt thereof.

8. (Original) A compound of formula I according to claim 1, selected from the group consisting of

{4-[3-(2,3-dimethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(2,3-dimethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[3-(2-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(2-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[1-(2-dimethylamino-ethyl)-5-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[1-(2-dimethylamino-ethyl)-3-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[5-(2,4-dichloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4-dimethoxy-phenyl)-amine;  
 {4-[3-(2,4-dichloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4-dimethoxy-phenyl)-amine;  
 4-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-benzoic acid;  
 (4-Methyl-piperazin-1-yl)-{4-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-methanone;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 {4-[3-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;

{4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 [4-(4-methyl-piperazin-1-yl)-phenyl]-[4-(1-methyl-5-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 [4-(4-methyl-piperazin-1-yl)-phenyl]-[4-(1-methyl-3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-[4-(1-methyl-5-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-[4-(1-methyl-3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4-dimethoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4-dimethoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;  
 {4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[5-(4-chloro-phenyl)-1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[3-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[5-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[3-(4-chloro-phenyl)-1-(1-methyl-piperidin-4-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;

{4-[5-(4-chloro-phenyl)-1-(1-methyl-piperidin-4-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[1-(2-dimethylamino-ethyl)-5-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 {4-[1-(2-dimethylamino-ethyl)-3-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-{4-[1-(1-methyl-piperidin-4-yl)-5-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-{4-[1-(1-methyl-piperidin-4-yl)-3-p-tolyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-[3-(4-chloro-3-methyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4-dimethoxy-phenyl)-amine;  
 (3-methoxy-phenyl)-{4-[3-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 (3-methoxy-phenyl)-{4-[1-methyl-3-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 (3-methoxy-phenyl)-{4-[1-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-[1-(2-dimethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;  
 {4-[3-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[5-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 [4-(4-methyl-piperazin-1-yl)-phenyl]-{4-[3-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 [4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-{4-[3-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 [4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-(3-trifluoromethoxy-phenyl)-amine;  
 (4-methanesulfonyl-phenyl)-{4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 (3-{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-methane-sulfonyl-phenyl)-amine;  
 {(3-methoxy-phenyl)-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 (3-methoxy-phenyl)-{4-[3-(3-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;

[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

{4-[3-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;

{4-[5-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;

{4-[3-(4-chloro-phenyl)-1-(1-methyl-piperidin-4-ylmethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;

{4-[5-(4-chloro-phenyl)-1-(1-methyl-piperidin-4-ylmethyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-phenyl)-amine;

[4-(4-ethyl-piperazin-1-yl)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-{4-[3-(3-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;

2-(4-{4-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-benzyl}-piperazin-1-yl)-ethanol;

{4-[3-(4-chloro-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[3-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-amine;

3-{4-[3-(3,5-dimethoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzenesulfonamide;

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amine;

[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(1H-tetrazol-5-yl)-phenyl]-amine;

[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-[4-(1-methyl-3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-[4-(1-methyl-5-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-[(2,2,6,6-tetramethyl-piperidin-4-ylamino)-methyl]-phenyl}-amine;

[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-{4-[(2,2,6,6-tetramethyl-piperidin-4-ylamino)-methyl]-phenyl}-amine;

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-ethyl-piperazin-1-yl)-phenyl]-amine;



{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-piperazin-1-yl-phenyl)-amine;  
 [3-(1-methyl-piperidin-4-yloxymethyl)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 [3-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 [3-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-[4-(1-methyl-3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine;  
 4-[4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-benzenesulfonamide  
 and pharmaceutically acceptable salts thereof.

9. (Original) A compound of formula I according to claim 2, selected from the group consisting of

{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-di methyl-amino-ethoxy)-phenyl]-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-diethylamino-ethoxy)-phenyl]-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-amine;  
 {4-[3-(3-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine;  
 {4-[3-(3-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-amine;  
 {4-[3-(3-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-diethylamino-ethoxy)-phenyl]-amine;  
 {4-[3-(3-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(4-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(4-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-amine;  
 {4-[3-(4-ethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;

{4-(2-diethylamino-ethoxy)-phenyl}-{4-[3-(4-ethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-(2-diethylamino-ethoxy)-phenyl}-{4-[3-(4-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-(2-diethylamino-ethoxy)-phenyl}-{4-[3-(3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-[3-(3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(2-morpholin-4-yl-ethoxy)-phenyl}-amine;  
 {4-[3-(3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(4-methyl-piperazin-1-yl)-phenyl}-amine;  
 {4-(2-dimethylamino-ethoxy)-phenyl}-{4-[3-(4-ethyl-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-(4-methyl-piperazin-1-yl)-phenyl}-{4-(3-m-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 {4-(2-diethylamino-ethoxy)-phenyl}-{4-(3-m-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 {4-(2-dimethylamino-ethoxy)-phenyl}-{4-(3-m-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 {4-[3-(3,4-dichloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(2-dimethylamino-ethoxy)-phenyl}-amine;  
 {4-[3-(3,4-dichloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(4-methyl-piperazin-1-yl)-phenyl}-amine;  
 {4-[3-(4-benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(2-dimethylamino-ethoxy)-phenyl}-amine;  
 4-{4-[2-{4-(4-methyl-piperazin-1-yl)-phenylamino}-pyrimidin-4-yl]-1H-pyrazol-3-yl}-phenol;  
 {4-(4-methyl-piperazin-1-yl)-phenyl}-{4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 {4-(2-dimethylamino-ethoxy)-phenyl}-{4-(3-p-tolyl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{3-(1-methyl-piperidin-4-ylmethoxy)-phenyl}-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(1-methyl-piperidin-4-ylmethoxy)-phenyl}-amine;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{3-(4-methyl-piperazin-1-yl)-phenyl}-amine;  
 4-{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzoic acid;  
 (4-{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;  
 {4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-{4-(4-methyl-piperazin-1-ylmethyl)-phenyl}-amine;

{4-[3-(2,4-dichloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[3-(2,4-dichloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 N-{4-[3-(4-chloro-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-N',N'-dimethyl-benzene-1,3-diamine;  
 {4-[3-(4-ethoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;  
 {4-[3-(4-ethoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 {4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 3-{4-[3-(4-chloro-3-hydroxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzenesulfonamide;  
 3-{4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzenesulfonamide;  
 3-{4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzoic acid ethyl ester;  
 3-{4-[3-(4-chloro-3-hydroxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-benzoic acid ethyl ester;  
 1-(3-{4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-ethanone;  
 benzothiazol-6-yl-{4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amine;  
 {4-[3-(4-chloro-3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(1-oxo-benzothiazol-6-yl)-amine;  
 [4-(3-benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-(3,4,5-trimethoxy-phenyl)-amine;  
 3-[4-(3-benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-benzoic acid tert-butyl ester;  
 3-[4-(3-benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-benzenesulfonamide;  
 [4-(3-benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-pyrimidin-2-yl}-(3-methylsulfanyl-phenyl)-amine;  
 and pharmaceutically acceptable salts thereof.


10. (Withdrawn) A compound of formula I, or a pharmaceutically acceptable salt thereof, according to claim 1 for use in a method for the treatment of the human or animal body.

11. (Previously Presented) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, together with at least one pharmaceutically acceptable carrier.


12. (Canceled)

13. (Withdrawn) ~~A method for the treatment of a disease which responds to an inhibition of a protein-tyrosine kinase comprising administering a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.~~

14. (Previously Presented) A process for the preparation of a compound of formula I according to claim 1 or of a salt of such a compound, characterized in that  
a) a compound of formula II




wherein Y is a leaving group such as halogen,  $-S(=O)-CH_3$  or  $-S(O_2)-CH_3$  and  $R_2$ ,  $R_3$  and  $R_3'$  have the meanings as defined for a compound of formula I according to claim 1, is reacted with a compound of formula III



wherein m and  $R_1$  have the meanings as defined for a compound of formula I according to claim 1;

b) in order to prepare a compound of formula I, wherein  $R_1$  is a radical  $R_5-C(=O)-$  in which  $R_5$  is mono- or di-substituted amino or a heterocyclic radical that is bound to the carbonyl moiety via a nitrogen ring atom, a compound of formula IV



wherein  $R_2$ ,  $R_3$  and  $R_3'$  have the meanings as defined for a compound of formula I according to claim 1, or a reactive carboxylic acid derivative thereof, is reacted with a mono- or di-substituted amine or a heterocyclic radical containing at least one nitrogen ring atom to which a hydrogen is bound, respectively; or

c) in order to prepare a compound of formula I, wherein  $R_2$  is unsubstituted or substituted lower alkyl or a heterocyclic radical, a compound of formula I, wherein  $R_2$  is hydrogen, is reacted with a compound of the formula  $R_2-OH$ , wherein  $R_2$  is unsubstituted or substituted lower alkyl or a heterocyclic radical wherein the substituted lower alkyl or the heterocyclic radical is attached to the hydroxy group of  $R_2-OH$  via a carbon atom of the lower alkyl moiety or via a carbon ring atom of the heterocyclic radical, respectively;

whereby functional groups which are present in the starting compounds of processes a) to c) and are not intended to take part in the reaction, are present in protected form if necessary, and protecting groups that are present are cleaved, whereby the said starting compounds may also exist in the form of salts provided that a salt-forming group is present and a reaction in salt form is possible;

and, if so desired, a compound of formula I thus obtained is converted into another compound of formula I, a free compound of formula I is converted into a salt, an obtained

salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.